Quantitative 7T Phase Imaging in Premanifest Huntington Disease

BACKGROUND AND PURPOSE: In vivo MR imaging and postmortem neuropathologic studies have demonstrated elevated iron concentration and atrophy within the striatum of patients with Huntington disease, implicating neuronal loss and iron accumulation in the pathogenesis of this neurodegenerative disorder. We used 7T MR imaging to determine whether quantitative phase, a measurement that reflects both iron content and tissue microstructure, is altered in subjects with premanifest Huntington disease. MATERIALS AND METHODS: Local field shift, calculated from 7T MR phase images, was quantified in 13 subjects with premanifest Huntington disease and 13 age- and sex-matched controls. All participants underwent 3T and 7T MR imaging, including volumetric T1 and 7T gradient recalled-echo sequences. Local field shift maps were created from 7T phase data and registered to caudate ROIs automatically parcellated from the 3T T1 images. Huntington disease–specific disease burden and neurocognitive and motor evaluations were also performed and compared with local field shift. RESULTS: Subjects with premanifest Huntington disease had smaller caudate volume and higher local field shift than controls. A significant correlation between these measurements was not detected, and prediction accuracy for disease state improved with inclusion of both variables. A positive correlation between local field shift and genetic disease burden was also found, and there was a trend toward significant correlations between local field shift and neurocognitive tests of working memory and executive function. CONCLUSIONS: Subjects with premanifest Huntington disease exhibit differences in 7T MR imaging phase within the caudate nuclei that correlate with genetic disease burden and trend with neurocognitive assessments. Ultra-high-field MR imaging of quantitative phase may be a useful approach for monitoring neurodegeneration in premanifest Huntington disease.

[1]  Julien Milles,et al.  Texture analysis of ultrahigh field T2*‐weighted MR images of the brain: Application to Huntington's disease , 2014, Journal of magnetic resonance imaging : JMRI.

[2]  S. Finkbeiner,et al.  Executive functions in premanifest Huntington's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[3]  J. R. Reichenbach,et al.  Effect of Age on MRI Phase Behavior in the Subcortical Deep Gray Matter of Healthy Individuals , 2013, American Journal of Neuroradiology.

[4]  J. Kramer,et al.  New Sensitive Measures of Executive Functioning in Premotor Huntington's Disease (S20.002) , 2013 .

[5]  Andrew G. Webb,et al.  Elevated brain iron is independent from atrophy in Huntington's Disease , 2012, NeuroImage.

[6]  Jane S. Paulsen,et al.  Cognitive domains that predict time to diagnosis in prodromal Huntington disease , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  Torsten Rohlfing,et al.  MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping , 2011, NeuroImage.

[8]  Jane S. Paulsen,et al.  Indexing disease progression at study entry with individuals at‐risk for Huntington disease , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[9]  R. Roos,et al.  Seven-year clinical follow-up of premanifest carriers of Huntington's disease , 2011, PLoS currents.

[10]  B. Leavitt,et al.  Development of biomarkers for Huntington's disease , 2011, The Lancet Neurology.

[11]  Stephen M. Smith,et al.  A Bayesian model of shape and appearance for subcortical brain segmentation , 2011, NeuroImage.

[12]  Jane S. Paulsen,et al.  Neurocognitive signs in prodromal Huntington disease. , 2011, Neuropsychology.

[13]  "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. , 2010, The Journal of neuropsychiatry and clinical neurosciences.

[14]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[15]  D. Yablonskiy,et al.  Biophysical mechanisms of phase contrast in gradient echo MRI , 2009, Proceedings of the National Academy of Sciences.

[16]  E. Haacke,et al.  Susceptibility-Weighted Imaging: Technical Aspects and Clinical Applications, Part 1 , 2008, American Journal of Neuroradiology.

[17]  S. Nelson,et al.  Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron , 2008, Annals of neurology.

[18]  G. Egan,et al.  Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease , 2008, Brain Research Reviews.

[19]  Bruce Fischl,et al.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.

[20]  Daniel B. Vigneron,et al.  Development of a robust method for generating 7.0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases , 2008, NeuroImage.

[21]  Jane S. Paulsen,et al.  Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[22]  Carlo Ciulla,et al.  Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain , 2007, Journal of magnetic resonance imaging : JMRI.

[23]  Jim Mintz,et al.  Myelin Breakdown and Iron Changes in Huntington’s Disease: Pathogenesis and Treatment Implications , 2007, Neurochemical Research.

[24]  Jane S. Paulsen,et al.  Preparing for preventive clinical trials: the Predict-HD study. , 2006, Archives of neurology.

[25]  Daniela Berg,et al.  Role of Iron in Neurodegenerative Disorders , 2006, Topics in magnetic resonance imaging : TMRI.

[26]  B. Harper Huntington Disease , 2005, Journal of the Royal Society of Medicine.

[27]  J. Ashburner,et al.  Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  E. Haacke,et al.  Imaging iron stores in the brain using magnetic resonance imaging. , 2005, Magnetic resonance imaging.

[29]  Shihua Li,et al.  Huntington and its Role in Neuronal Degeneration , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[30]  Abraham Z. Snyder,et al.  A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume , 2004, NeuroImage.

[31]  Petra Schmalbrock,et al.  Enhanced gray and white matter contrast of phase susceptibility‐weighted images in ultra‐high‐field magnetic resonance imaging , 2003, Journal of magnetic resonance imaging : JMRI.

[32]  Michael Brady,et al.  Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images , 2002, NeuroImage.

[33]  N Makris,et al.  Striatal volume loss in HD as measured by MRI and the influence of CAG repeat , 2001, Neurology.

[34]  G. Bartzokis,et al.  MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. , 2000, Cellular and molecular biology.

[35]  G. Pearlson,et al.  Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[36]  G. Bartzokis,et al.  Increased basal ganglia iron levels in Huntington disease. , 1999, Archives of neurology.

[37]  R M Henkelman,et al.  MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. , 1993, AJNR. American journal of neuroradiology.

[38]  B Horwitz,et al.  Age-related differences in volumes of subcortical nuclei, brain matter, and cerebrospinal fluid in healthy men as measured with magnetic resonance imaging. , 1992, Archives of neurology.

[39]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.